SCHEMBL6428704

SCHEMBL6428704

CCOC(=O)c1ccc(/C=C(/c2ccc3c(c2)C(C)(C)CCC3(C)C)[Si](C)(C)C)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 12/20 0.54
RARA P10276 12/20 0.54
RARG P13631 11/20 0.54
RXRA P19793 10/20 0.54
RXRG P48443 6/20 0.54
RXRB P28702 6/20 0.54
CYP3A4 P08684 5/20 0.39
CYP26A1 O43174 4/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
GMNN O75496 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2D6 P10635 1/20 0.39
NFKB1 P19838 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427528 0.88 RXRA (0.56) RARBRARARARGRXRARXRG
SCHEMBL10399347 0.87 RARG (0.72) RARBRARARARGRXRARXRG
SCHEMBL10399345 0.87 RARG (0.72) RARBRARARARGRXRARXRG
SCHEMBL177719 0.85 RXRA (0.73) RARBRARARARGRXRARXRG
SCHEMBL177720 0.85 RXRA (0.73) RARBRARARARGRXRARXRG
SCHEMBL6428631 0.82 RARA (0.53) RARBRARARARGRXRARXRG
SCHEMBL28749819 0.82 RARA (0.53) RARBRARARARGRXRARXRG
SCHEMBL6259442 0.79 RXRA (0.48) RARBRARARARGRXRARXRG
SCHEMBL6259440 0.79 RXRA (0.48) RARBRARARARGRXRARXRG
SCHEMBL7219497 0.78 RXRA (0.74) RARBRARARARGRXRARXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 US disclosed
US-6906057-B1 Methods for modulating FXR receptor activity ALLERGAN, INC. (US) 2005-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 RARB 3345/4885RARA 2919/4885RARG 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.